Recent Articles from GlobeNewswire

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise)

SANTA CLARA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API) (the “Company”), a pioneer and leader in conversational AI and real-time engagement technology, today announced its unaudited financial results for the second quarter ended June 30, 2026.

The acquisition demonstrates Foods Connected’s commitment to expanding quality and food safety capabilities in North America and Australia.

LONDON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”), a provider of ESG, sustainability and compliance solutions to institutional and corporate clients globally, today announced its consolidated financial and operational results for the fiscal year ended March 31, 2026 (“FY2026”).

Revenue and Net Income Increase QoQ and YoY

PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) --

AIRJ Signs Exclusive Sales Agreement with Kubota Corporation, Commissions First Full-Scale AirJoule Prime System, and Extends Commercialization into the UAE

- Assets Under Management (“AuM”) Increased 13.4% Year-over-Year to $31.6 Billion -

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) --

GREENWICH, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Stardust Power Inc. (Nasdaq: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced the results for the quarter ended June 30, 2026 and provided an update on the continued advancement of its proposed lithium refinery project in Muskogee, Oklahoma.

(All amounts in Canadian dollars unless otherwise noted)

HERNDON, Va., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced that its board of directors approved a 2026 third quarter dividend of $0.16 per share on the company's common stock.

VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) reports interim financial results for the quarter ended June 30, 2026. The interim financial statements and management’s discussion and analysis (“MD&A”) are available on Skeena’s website, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) --

Only Two-Time Champion in Contest History Posts a Profit More Than Double the Field — Then Sets Sights on Football's Toughest Test: Preseason

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience 

OAKLAND, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB: LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2026.

ATLANTA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that its Board of Directors approved a quarterly dividend of $0.476563 per share to Series B Cumulative Perpetual Preferred shareholders. The cash dividend will be paid on or about September 15, 2026 to holders of record of Atlanticus’ Series B Cumulative Perpetual Preferred Stock on the close of business on September 1, 2026.

Gemini increased total revenue 37% YoY in Q2 2026, with a 149% YOY increase in services revenue highlighting increasingly diversified revenue amid a 38% YOY drop in exchange transaction revenue as crypto market remains soft

Announced definitive agreement to acquire PCI Geomatics, creating a vertically integrated geospatial intelligence platform, scheduled to close in Q3 2026

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027

THE WOODLANDS, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- TWFG, Inc. (Nasdaq: TWFG) ("TWFG" or the "Company") today announced that it has entered into an Amended and Restated Credit Agreement providing for a $125 million revolving credit facility and extending the facility's maturity to August 12, 2031.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against UWM Holdings Corporation (“UWM Holdings” or the “Company”) (NYSE: UWMC).

EDEN PRAIRIE, Minn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor recreation product manufacturer, today announced strategic actions to optimize its manufacturing footprint, enhance operational efficiency and position its premium brands for long-term growth.

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --

Benchmark Set for Disclosed Restoration as High Demand for Vintage Sports Collectibles Persists

Accelsius focused on execution against foundational milestones to strengthen path to scaled two-phase adoption

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (www.aftlaw.com), a nationally recognized law firm focusing on protecting investors’ rights, informs shareholders that it is investigating potential violations of federal securities laws by Jefferies Financial Group Inc. (“Jefferies”) (NYSE:JEF), and Jefferies’ directors and officers. The investigation is focused on whether Jefferies or its executives made false or misleading statements or failed to disclose material information to investors.

EL DORADO HILLS, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (NASDAQ: BZAI, NASDAQ: BZAIW) (“Blaize,” the “Company,” “we,” “us,” and “our”) , a leader in programmable, energy-efficient edge AI computing, today reported financial results for the second quarter ended June 30, 2026.

A patient-centered initiative focused on education, connection, and support

Summary: Matador generated gross proceeds of approximately $1.1 million under its ATM Program during the reporting period ended July 31, 2026, bringing aggregate gross proceeds since the program commenced to approximately $2.3 million. Capital deployment via the ATM Program continues to support Bitcoin acquisition and, on a parallel basis, the Company’s Bitcoin yield generation strategy conducted in collaboration with Galaxy.

Expanded first-half GAAP gross margin to 31.0% from 11.8% and non-GAAP gross margin to 29.0% from 4.9% in the prior year

DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.

Completed separation from The Middleby Corporation on July 6, 2026

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with significant expertise in building influencer lead brands, live-steam shopping and social commerce, today announced its financial results for the quarter ended June 30, 2026.

Ended Second Quarter 2026 With $183.9 Million in Cash, Cash Equivalents, and Short Term Investments, and No Debt

Commercialization execution advances in Rice and Sustainable Ingredients

NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.

Firefly will complete design review for Elytra mission providing deorbit services

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL --

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026

EMERYVILLE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2026 financial results, provided operational highlights and outlined expected upcoming milestones.    

Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial

FAIRFAX, Va., Aug. 13, 2026 (GLOBE NEWSWIRE) -- WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobility Management solutions, reported results for the second quarter ended June 30, 2026.

Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

TPV reached nearly US$18 billion (+92% year-over-year), the 7th consecutive quarter of 50%+ growth, and continued acceleration over the last 5 quarters.Record gross profit: US$127 million (+29% year-over-year). Operating profit: US$64 million (+15% year-over-year), with Operating Profit/Gross Profit ratio reaching 50% (+6 p.p. quarter-over-quarter); operating leverage to improve in the second half of 2026. Net income at US$55 million (+28% year-over-year), diluted EPS $0.18 (vs. $0.14 in 1Q26). Adj. Free Cash Flow US$69 million (+41% year-over-year), Adj. FCF/Net income conversion of 125%. Guidance update: TPV guidance raised to 60–70% year-over-year and Gross profit to 25–30% year-over-year; Operating profit guidance maintained at 27.5–32.5% year-over-year.

Management to Host Conference Call Today at 4:30 p.m. ET

Collections Grow 18% to $300.9 Million and Deployments grow 21% to $152.2 MillionEstimated Remaining Collections (“ERC”) up 18% to $3.4 BillionPre-tax Income of $53.3 Million with Net Income of $41.3 Million and EPS of $0.67Adjusted Pre-tax Income of $59.3 Million with Adjusted Net Income of $47.3 Million and Adjusted EPS of $0.77Board of Directors Declares Quarterly Cash Dividend of $0.24 per Share

– Net cash used in operating activities only $319K in the second quarter –– Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash –– July monthly Zola® sales top $740K; exceed $1 million through first week of August –

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN) ("Roadzen" or the "Company"), a global leader in AI at the convergence of insurance and mobility, today announced its financial results for the three months ended June 30, 2026, its first quarter of fiscal year 2027.

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026

Key Takeaways:

Record July margins, improving financial metrics and proposed TYTL combination position Beeline for continued growth and operating leverage despite macro headwinds

WILMINGTON, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the platform for agentic AI banking, will report financial results for its second quarter ended July 31, 2026, after the market close on Tuesday, August 25, 2026. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results.

Revenue reached $5.1 million; Gross margin improved to 90% from 80% in the prior year 

39% Revenue Increase and 47% Growth in U.S. Procedures

MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported second quarter 2026 financial results and provided updates on its programs.

Southfield, Michigan, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been named one of PEOPLE Magazine’s 100 Companies That Care® by Great Place To Work® and PEOPLE magazine for the fifth consecutive year. Credit Acceptance was ranked 11th among the 100 companies that made the list, up 33 spots from last year.

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026

BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the second quarter ended June 30, 2026.

BOISE, Idaho, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) today launched the Micron Ventures Paradigm Fund, a $250 million investment vehicle built to partner with the companies shaping the future of AI. Micron Ventures’ third and largest fund to date, the Paradigm Fund will invest across the full AI technology stack, from model architectures and compute infrastructure to enterprise applications and physical AI.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), a leading developer of the world’s largest resource of critical metals essential to energy, defense, manufacturing and infrastructure, today provided a corporate update and second quarter financial results for the period ended June 30, 2026.

SANTA CLARA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc. (NASDAQ: AMAT) today reported results for its third quarter ended July 26, 2026.

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026

$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) ("IREN") today announced that it will release its financial results for the fiscal year ended June 30, 2026, on Thursday, August 27, 2026 and host a conference call beginning at 5:00 p.m. Eastern Time.

Nationwide media tour conducted by Coalition to Empower our Future in conjunction with D S Simon Media discussing new research finding voters and parents believe banning or heavily restricting access to phones and technology could have unintended consequences for young people.

Second quarter revenue growth of 16% to $27.2 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET

Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –